Nextech Invest, a venture capital and private equity firm, led a $75m Series B funding round in Alpha-9 Theranostics, a clinical stage company developing differentiated and highly targeted radiopharmaceuticals, with participation from Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital and BVF Partners. "We have always believed in the company, its founders, and the potential for radiotherapies to effectively address a wide range of cancers. Our team has done excellent work progressing our pipeline of novel radiopharmaceuticals over the last year, and we are excited to have the support of these top-tier investors. With this new investor partnership, we are well positioned to progress multiple targets into the clinic, harnessing the potential of radiopharmaceuticals to realize more effective treatments for people living with cancer," David Hirsch, Alpha-9 CEO.